antibody technologies
that change the game!

new/era/mabs redefines antibody discovery

what's in it for you?

new/era/mabs GmbH is a privately financed biotech company with a proprietary technology platform for the generation of monoclonal and recombinant antibodies for use in research, diagnostic and therapeutic applications.

We provide high-end antibody discovery workflows four times faster than conventional state-of-the-art processes. The platform core component is selma - a highly flexible selection process for antibody-producing cells based on novel transgenic fusion cell lines.

We offer the customized generation and production of mouse, camelid, and human antibodies for various in vitro and in vivo applications. We permanently expand our R&D segment with next-generation platform add-ons and hold all intellectual property rights as different patent families.

Founded in 2014 as an university spin-off located at the Potsdam Science Park the company is embedded in a vibrant scientific environment.

Are you ready to enter a new era of antibody generation?

get in touch

meet selma
our groundbreaking technology

antibody technologies that change the game!

Antibodies are wonderful and reliable tools but the generation so far is tedious and resource intensive. Selecting suitable antibodies is highly complex. When using selma as selection tool you can absolutely rely on having a fast, efficient and highly flexible technology to select your desired antibody producing cell.

learn more

selma + murine monoclonal antibodies

The induction of specific antibody responses in mice is performed by immunizing with the antigen of choice. To increase the efficacy of this process we developed a hyper-immunization protocol based on viral carrier proteins. In combination with selma as selection tool we provide a high end solution for the discovery of antibody producing hybridoma cells four times faster than with conventional methods.

learn more

selma + human monoclonal antibodies

We use a fast and reliable workflow for human monoclonal antibodies, too. Human B cells are specifically activated by our proprietary in vitro immunization (IVI). Either customized antigens or our virus-derived antigen carriers are used for the antigen-specific immunization. And, how would you select the desired antibody-producing cells? You are absolutely right if your answer is - selma!

learn more

selma + camelid recombinant antibodies

Camelid antibodies were recently spotlighted due to their exclusive properties such as a high temperature stability which would allow workflows without needing a cool chain. This is a very interesting feature for in vitro diagnostic applications. We carry out the generation of either variable heavy chain antibody fragments (15 kDa) or full length heavy chain only antibodies (90 kDa) for the establishment of a specific test environment. We either use our proprietary naïve camelid antibody library or individually created custom immune libraries for identification. Again, antibody-producing mammalian cells are selected with selma.

learn more

selma published in nature

A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line.

read article

selma published in Science

In this Science webinar, Katja Hanack demonstrates how selma significantly simplifies and accelerates antibody characterization by flow cytometry.

After a free registration you can start the recording at 23:17 min.

view webinar

what our partners are saying?

  • The cooperation with Katja and her team is incredible and helps us to develop our products much faster and with higher efficacy. We are very convinced of the quality of their work and the reliability and passion to solve any custom-related issues.

    Prof. Dr. Dirk Roggenbuck
    CEO of Medipan and Generic Assays
  • Katja and I collaborate in a SARS-CoV2 project where new/era/mabs provides specific camelid antibodies for our test device. I´m very proud to have her on board. Using the antibody specific support from her team will essentially foster the successful implementation of our device.

    Prof. Venkatesan Renugopalakrishnan
    Harvard Medical School and Northeastern University
  • Creating innovative antibodies with new/era/mabs was a snap. Within a few short weeks, we received high affinity purified potent antibodies, allowing our research on auto-immune encephalitis to move forward quickly. Highly recommended!

    Prof. Craig Garner
    German Centre for Neurodegenerative Diseases and founder of SPARK Berlin
  • I'm very impressed by the technology, Katja and her team developed to select antibody producing cells. I strongly advocate her services.

    Prof. J Paul Banga
    King´s College London

the people behind

  • Katja Hanack, PhD, MBA
    President & CEO

    Katja is a renowned expert in antibody discovery and engineering and co-inventor of selma - the proprietary selection technology for a high throughput sorting of antibody-secreting cells. As a Professor of Immunotechnology at the University of Potsdam she experienced both sides as an academic and entrepreneur. She is the author of more than 25 peer-reviewed articles and co-inventor of 5 patents.

  • Björn Lindemann, PhD
    Business Development

    Björn is a molecular biologist and has more than 30 years of experience in the biotech industry. He was a founding team member and Vice President of Evotec and CSO of life science incubator/investor BioAgency. As a serial entrepreneur, senior executive and board member he founded several biotech companies and held numerous leadership positions with responsibilities in various life science areas.

  • Claus Simandi
    Patent Attorney

    Claus's expertise includes supporting patent granting and opposition proceedings, as well as litigation and licensing, particularly in the fields of chemistry, biotechnology, pharmaceuticals, cosmetics, and diagnostics. Before founding his own firm in 2006, he worked in the patent departments of Aventis Research & Technologies and Hoffmann La Roche and at Dreiss Patentanwälte in Stuttgart.

  • Bianca Hartmann, PhD
    Antibody Research & Development

    Bianca received her PhD in neurobiology and metabolic diseases and switched from academia to industry in 2018. With her professional expertise she is working as senior scientist and project manager in antibody discovery and selection projects at new/era/mabs.

  • Anja Schlör, MSc
    Antibody Research & Development

    Anja did her Master´s degree in biochemistry and molecular biology in 2017 and worked on the development of novel phage display workflows for the specific enrichment of camelid single-domain antibodies. In 2020 she joined new/era/mabs as an expert for the generation of recombinant human and camelid antibodies.

  • Nicole Hebel, MSc
    Antibody Research & Development

    Nicole is an experienced Master of Science in the field of cellular biology, flow cytometry based workflows and protein purification. She joined new/era/mabs in 2018 bringing in her valuable expertise to effectively manage customized antibody discovery campaigns.

  • Anja Hönow, MSc
    Antibody Research & Development

    Anja received her Master´s degree in Biotechnology in 2013 and acquired different experiences in industry and academia. In 2021 she joined new/era/mabs to focus on the generation and selection of human antibodies using selma as technology platform.